Previous 10 | Next 10 |
A look at the top 10 most actives in the United States PROSHARES TRUST (SQQQ) fell 3.4% to $12.34 on volume of 161,376,033 shares New York Community Bancorp Inc. (NYCB) fell 11.1% to $5.75 on volume of 125,980,698 shares Plug Power Inc. (PLUG) rose 5.6% to $4.7 on volume of 111,112,179 sh...
2024-02-01 13:34:44 ET More on Atara Biotherapeutics Atara Biotherapeutics: Market Overreaction To Failed MS Study Creates Buy Opportunity Atara's Balancing Act: Innovation On A Fiscal Tightrope Atara Biotherapeutics, Inc. (ATRA) Q3 2023 Earnings Call Transcript ...
First Phase 3 Results Published for an Allogeneic T-Cell Therapy Significant 51.2% Objective Response Rate and 23.0 Month Median Duration of Response in Relapsed or Refractory EBV+ PTLD Patients U.S. BLA on Track for Submission in Q2 2024 Based on Strong Clinical File ...
2024-01-08 09:47:36 ET More on Atara Biotherapeutics Atara Biotherapeutics: Market Overreaction To Failed MS Study Creates Buy Opportunity Atara's Balancing Act: Innovation On A Fiscal Tightrope Atara Biotherapeutics, Inc. (ATRA) Q3 2023 Earnings Call Transcript ...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it has entered into a definitive agre...
Closing of Transaction with Pierre Fabre Laboratories to Expand Global Tab-cel ® Partnership Tab-cel BLA on Track for Submission in Q2 2024 Following Positive New Data from Pivotal ALLELE Study Expansion of Next-gen Allogeneic CAR-T Portfolio to Autoimmune Disease ...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Exe...
2023-12-21 09:55:17 ET DENVER, Colo., Dec. 21, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; HOOKIPA Pharma Inc (NASDAQ: HOOK), ParaZero Technologies Ltd (NASDAQ: PRZO), Atara Biotherapeutics Inc (NASDA...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the closing of the expanded global partn...
2023-12-19 12:14:25 ET More on Atara Biotherapeutics Atara Biotherapeutics: Market Overreaction To Failed MS Study Creates Buy Opportunity Atara's Balancing Act: Innovation On A Fiscal Tightrope Atara Biotherapeutics, Inc. (ATRA) Q3 2023 Earnings Call Transcript ...
News, Short Squeeze, Breakout and More Instantly...
Atara Biotherapeutics Inc. Company Name:
ATRA Stock Symbol:
NASDAQ Market:
Atara Biotherapeutics Inc. Website:
Tab-cel ® U.S. BLA on Track for Submission in Q2 2024 Initiation of ATA3219 Lupus Nephritis Study Expected in Q4 2024, with Initial Clinical Data Expected in H1 2025 Initiation of New ATA3219 Cohort Without Lymphodepletion in Severe Systemic Lupus Erythematosus Planned fo...
Tab-cel ® U.S. BLA on Track for Submission in Q2 2024 Following Positive Pre-BLA Meeting Allogeneic CAR T Pipeline Expands Into Autoimmune Disease With Plans to Initiate an ATA3219 Lupus Nephritis Study in H2 2024, and Initial Clinical Data Expected H1 2025 AT...